Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | PIK3CA |
| Variant | Q546K |
| Impact List | missense |
| Protein Effect | gain of function |
| Gene Variant Descriptions | PIK3CA Q546K lies within the PIK helical domain of the Pik3ca protein (UniProt.org, PMID: 17376864). Q546K confers a gain of function to Pik3ca as indicated by constitutive phosphorylation of downstream targets Akt and S6, and is transforming in cell culture (PMID: 17376864, PMID: 29533785). |
| Associated Drug Resistance | |
| Category Variants Paths |
PIK3CA mutant PIK3CA act mut PIK3CA Q546K PIK3CA mutant PIK3CA exon10 PIK3CA Q546X PIK3CA Q546K |
| Transcript | NM_006218.4 |
| gDNA | chr3:g.179218306C>A |
| cDNA | c.1636C>A |
| Protein | p.Q546K |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| XM_006713658 | chr3:g.179218306C>A | c.1636C>A | p.Q546K | RefSeq | GRCh38/hg38 |
| XM_006713658.4 | chr3:g.179218306C>A | c.1636C>A | p.Q546K | RefSeq | GRCh38/hg38 |
| XM_011512894.2 | chr3:g.179218306C>A | c.1636C>A | p.Q546K | RefSeq | GRCh38/hg38 |
| NM_006218 | chr3:g.179218306C>A | c.1636C>A | p.Q546K | RefSeq | GRCh38/hg38 |
| XM_011512894 | chr3:g.179218306C>A | c.1636C>A | p.Q546K | RefSeq | GRCh38/hg38 |
| XM_006713658.5 | chr3:g.179218306C>A | c.1636C>A | p.Q546K | RefSeq | GRCh38/hg38 |
| NM_006218.3 | chr3:g.179218306C>A | c.1636C>A | p.Q546K | RefSeq | GRCh38/hg38 |
| NM_006218.4 | chr3:g.179218306C>A | c.1636C>A | p.Q546K | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PIK3CA Q546K | breast cancer | sensitive | Dactolisib | Preclinical | Actionable | In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007). | 26627007 |
| PIK3CA Q546K | breast cancer | sensitive | Alpelisib | Preclinical - Cell culture | Actionable | In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007). | 26627007 |
| PIK3CA Q546K | breast cancer | sensitive | MK2206 | Preclinical | Actionable | In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007). | 26627007 |
| PIK3CA Q546K | breast cancer | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007). | 26627007 |
| PIK3CA Q546K | breast cancer | sensitive | Neratinib | Preclinical | Actionable | In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007). | 26627007 |
| PIK3CA Q546K | breast cancer | sensitive | Trametinib | Preclinical | Actionable | In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007). | 26627007 |
| PIK3CA Q546K | Advanced Solid Tumor | sensitive | Trametinib | Preclinical | Actionable | In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007). | 26627007 |